J&J strikes $6.5 billion deal for autoimmune disease specialist Momenta

By Manas Mishra (Reuters) - Johnson & Johnson agreed to buy Momenta Pharmaceuticals Inc for about $6.5 billion on Wednesday, to bolster its portfolio of drugs for hard-to-treat autoimmune diseases. The acquisition, latest in a recent spate of healthcare deals, comes just days after France's Sanofi struck a $3.7 billion deal to buy Principia Biopharma Inc for its pipeline of autoimmune disease treatments

Reuters August 20, 2020 00:06:32 IST
J&J strikes $6.5 billion deal for autoimmune disease specialist Momenta

JJ strikes 65 billion deal for autoimmune disease specialist Momenta

By Manas Mishra

(Reuters) - Johnson & Johnson agreed to buy Momenta Pharmaceuticals Inc for about $6.5 billion on Wednesday, to bolster its portfolio of drugs for hard-to-treat autoimmune diseases.

The acquisition, latest in a recent spate of healthcare deals, comes just days after France's Sanofi struck a $3.7 billion deal to buy Principia Biopharma Inc for its pipeline of autoimmune disease treatments.

Treatments targeting autoimmune conditions have fetched billions of dollars in sales, including AbbVie Inc's Humira, which is the world's best selling drug.

J&J's Janssen unit will gain access to Momenta's experimental therapy, nipocalimab, which is in late-stage testing for warm antibody hemolytic anemia, a condition that causes destruction of healthy red blood cells, and mid-stage testing for myasthenia gravis, a neuromuscular disease.

Nipocalimab is expected to eventually win approval to treat several conditions, "many as first-in-class indications with potential for significant peak year sales, some of which could exceed $1 billion," J&J said in a statement.

"We find the deal modestly surprising as we see every one of Momenta's assets as somewhat tricky to develop," said BTIG analyst Thomas Shrader.

Shares of Cambridge, Massachusetts-based Momenta were up 69.2% at $52.15, just a hair's breadth away from the offer price of $52.50.

With the recent flurry of activity, the pharmaceutical and biotech sectors have seen 829 deals so far this year, compared with 839 by this time in 2019, according to data from Refinitiv.

The value of the deals, however, is much lower this year - $62 billion versus $290 billion a year ago.

J&J in recent years has sold some businesses such as the one that made medical devices for diabetes care, as it sharpens focus on better-performing products such as cancer treatments.

(Reporting by Manas Mishra in Bengaluru; Editing by Sherry Jacob-Phillips, Lewis Krauskopf and Shinjini Ganguli)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

France, Germany to agree to NATO role against Islamic State - sources
| Reuters
World

France, Germany to agree to NATO role against Islamic State - sources | Reuters

By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States

China's Xi says navy should become world class
| Reuters
World

China's Xi says navy should become world class | Reuters

BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.